KSE - Delayed Quote KRW

Celltrion, Inc. (068270.KS)

191,600.00 +2,300.00 (+1.22%)

At close: 3:30:27 PM GMT+9

Kaigene Enters into Exclusive Global Licensing Agreement with Celltrion for Next-Generation Anti-APRIL Antibody KG013

PR Newswire 8d ago

068270.KS
+1.22%
Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases

PR Newswire 11mo ago

068270.KS
+1.22%
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 2026

Business Wire 15d ago

068270.KS
+1.22%
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026

PR Newswire 19d ago

068270.KS
+1.22%
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.

PR Newswire 25d ago

068270.KS
+1.22%
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

Business Wire 2mo ago

068270.KS
+1.22%
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)

PR Newswire 6mo ago

068270.KS
+1.22%
Exploring Three High Growth Tech Stocks with Global Potential

Simply Wall St. 11mo ago

PHM.MC

300308.SZ

6805.TW
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation

PR Newswire 7mo ago

068270.KS
+1.22%
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

PR Newswire 9mo ago

068270.KS
+1.22%
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

GlobeNewswire 9mo ago

ABP

068270.KS
+1.22%
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

GlobeNewswire 10mo ago

ABP

068270.KS
+1.22%

U.S. markets closed

Celltrion, Inc. (068270.KS)

Kaigene Enters into Exclusive Global Licensing Agreement with Celltrion for Next-Generation Anti-APRIL Antibody KG013

Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 2026

Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026

OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)

Exploring Three High Growth Tech Stocks with Global Potential

Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation

Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers